Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
Authors:
- Michael RisteMRMichael Riste
- Julia L. MarshallJMJulia L. Marshall
- Iman SattiISIman Satti
- Stephanie A. HarrisSHStephanie A. Harris
- Morven WilkieMWMorven Wilkie
- Raquel Lopez RamonRRRaquel Lopez Ramon
- Danny WrightDWDanny Wright
- Rachel E. WittenbergRWRachel E. Wittenberg
- Samantha VermaakSVSamantha Vermaak
- Rebecca Powell DohertyRDRebecca Powell Doherty
- Alison LawrieALAlison Lawrie
- Christopher P. ConlonCCChristopher P. Conlon
Open Access
Abstract
The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a Phase I trial to evaluate the safety and immunogenicity of MVA85A delivered by aerosol in UK adults with LTBI (NCT02532036). Two volunteers were recruited, and the vaccine was well-tolerated with no safety concerns. Aerosolised vaccination with MVA85A induced mycobacterium- and vector-specific IFN-γ in blood and mycobacterium-specific Th1 cytokines in bronchoalveolar lavage. We identified several important barriers that could hamper recruitment into clinical trials in this patient population. The trial did not show any safety concerns in the aerosol delivery of a candidate viral-vectored TB vaccine to two UK adults with Mycobacterium tuberculosis (M.tb) infection. It also systemically and mucosally demonstrated inducible immune responses following aerosol vaccination. A further trial in a country with higher incidence of LTBI would confirm these findings.Keywords
Funding Information
- Wellcome Trust (WI 206331/Z/17/Z)
- TBVAC2020 (643381)
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (IS-BRC-1215-20008)
- TuBerculosis Vaccine Initiative (TBVI) /DFID ((TBVI) /DFID)
This publication has 28 references indexed in Scilit:
- Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of MacaquesClinical and Vaccine Immunology, 2013
- Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsVaccine, 2012
- A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis –infected AdultsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsBMJ Open, 2011
- Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis –infected IndividualsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Cell-Mediated Immune Responses in TuberculosisAnnual Review of Immunology, 2009
- Immunogenicity and safety of aerosolized measles vaccine: Systematic review and meta-analysisVaccine, 2008
- Intranasal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances Protection by Parenteral Mycobacterium bovis BCG Immunization against Pulmonary TuberculosisInfection and Immunity, 2006
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Altenative Routes of Measles Immunization: a ReviewBiologicals, 1997